公开(公告)号：EP2889307A1

公开(公告)日：2015-07-01

申请号：EP13828357.7

申请日：2013-06-18

申请人： Hainan University

发明人： LUO, Sulan ,  ZHANGSUN, Dongting ,  WU, Yong ,  ZHU, Xiaopeng ,  HU, Yuanyan ,  BING, Hui ,  MCINTOSH, J., Michael

IPC分类号： C07K7/08 ,  C07K14/435 ,  C12N15/12 ,  C12N15/63 ,  C12N1/21 ,  C12N1/19 ,  C07K19/00 ,  A61K38/10 ,  A61K38/17 ,  A61P25/04 ,  A61P25/16 ,  A61P25/28 ,  A61P25/34 ,  A61P25/36 ,  A61P29/00 ,  C07K1/04 ,  C07K1/06 ,  C07K1/16

CPC分类号： C07K14/43504 ,  A61K38/00 ,  C07K1/061 ,  C07K1/16 ,  C07K1/30 ,  C07K2319/00 ,  G01N33/5032 ,  G01N33/944 ,  G01N2333/70571 ,  G01N2500/04

摘要： The present invention provides a novel α-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide. The present invention discloses a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The α-conotoxin peptide of the present invention can specifically block acetylcholine receptor (nAChRs, such as α3β2 nAChRs, α6/α3β2β3 nAChR or α3β4 nAChR or α6/α3β4 nAChR), has activity for treatment of neuralgia, addiction, Parkinson's disease, dementia, schizophrenia, cancers, and can be used in the manufacture of a medicament for analgesia and smoking cessation and drug-withdrawal, a medicament for treatment of mental diseases and cancers, as well as a tool drug for neurosciences.

摘要翻译： 本发明提供新型的± - 毒素肽，药物组合物及其用途。 本发明还提供了荚蛋毒素肽的前肽，核酸构建体，表达载体和芋螺毒素肽的转化细胞以及芋螺毒素肽的融合蛋白。 本发明公开了一种阻断乙酰胆碱受体的方法，以及在制造药物中使用芋头毒素肽。 本发明的± - 毒素肽可以特异性阻断乙酰胆碱受体（nAChRs，如±3 2 2 nAChRs，±6 /±3 2 2 3 3 nAChR或±3 2 4 nAChR或±6 /±3 2 4 nAChR），具有治疗神经痛，成瘾的作用 帕金森氏病，痴呆症，精神分裂症，癌症等，可用于制造用于镇痛和戒烟和药物戒断的药物，用于治疗精神疾病和癌症的药物，以及用于神经科学的工具药物。

公开(公告)号：EP2051726A4

公开(公告)日：2012-06-20

申请号：EP07796903

申请日：2007-07-17

申请人： UNIV UTAH RES FOUND

发明人： MCINTOSH J MICHAEL ,  OLIVERA BALDOMERO M ,  ELLISON MICHAEL A ,  VINCLER MICHELLE

IPC分类号： A61K38/17

CPC分类号： A61K38/1767 ,  G01N33/944 ,  G01N2500/00

摘要： The present invention relates to the use of compounds that block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block the α9α10 subtype of the nAChR.

摘要翻译： 本发明涉及阻断烟碱乙酰胆碱受体（nAChR）的α9α10亚型用于治疗诸如神经性疼痛和炎症性疼痛之类疼痛以及诸如关节炎的炎症性疾病的化合物的用途。 本发明还涉及筛选化合物以鉴定阻断nAChR的α9α10亚型的止痛剂。

公开(公告)号：EP1719512B1

公开(公告)日：2011-05-04

申请号：EP06017380.4

申请日：1999-03-26

申请人： PHYTOPHARM PLC

发明人： Xia, Zongqin ,  Hu, Yaer ,  Rubin, Ian ,  Brostoff, Jonathan ,  Whittle, Brian ,  Wang, Weijun ,  Gunning, Phil

IPC分类号： A61K31/58 ,  A61K31/70 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P39/00 ,  A61P43/00

CPC分类号： A61K31/704 ,  A61K31/58 ,  A61K31/7048 ,  A61K36/88 ,  A61K36/896 ,  A61K36/8964 ,  A61K36/8965 ,  A61K36/90 ,  G01N33/944

公开(公告)号：EP2015773A4

公开(公告)日：2010-05-05

申请号：EP07861297

申请日：2007-04-27

申请人： ANTERIOS INC

发明人： EDELSON JONATHAN

IPC分类号： A61K39/02

CPC分类号： G01N33/5088 ,  G01N33/944 ,  G01N2333/33

公开(公告)号：EP2051726A2

公开(公告)日：2009-04-29

申请号：EP07796903.8

申请日：2007-07-17

申请人： University of Utah Research Foundation

发明人： MCINTOSH, J., Michael ,  OLIVERA, Baldomero, M. ,  ELLISON, Michael, A. ,  VINCLER, Michelle

IPC分类号： A61K38/00

CPC分类号： A61K38/1767 ,  G01N33/944 ,  G01N2500/00

摘要： The present invention relates to the use of compounds that block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block the α9α10 subtype of the nAChR.

公开(公告)号：EP1831683A1

公开(公告)日：2007-09-12

申请号：EP05818153.8

申请日：2005-12-14

申请人： Pfizer Products Inc.

发明人： GROPPI, Vincent Edward Jr., Pfizer Global Research and Development ,  HURST, Raymond Stuart ,  PIOTROWSKI, David Walter

IPC分类号： G01N33/48 ,  A61P25/18 ,  A61P3/04 ,  A61K31/17 ,  A61K31/433 ,  A61K31/42 ,  A61K31/44

CPC分类号： A61K31/17 ,  A61K31/42 ,  A61K31/433 ,  A61K31/44 ,  G01N33/944 ,  Y02A50/411

摘要： The present invention provides methods for identifying compounds useful in modulating alpha7 nicotinic acetylcholine receptors. The invention also provides compounds that prevent, suppress or inhibit desensitization of an alpha7 nicotinic acetylcholine receptor, and which resensitize such receptors. Pharmaceutical compositions, and methods of treatment, particularly in regard of neurological diseases are also described.

公开(公告)号：EP1502110A4

公开(公告)日：2007-09-05

申请号：EP03741789

申请日：2003-05-09

申请人： MEMORY PHARM CORP

发明人： WANG DAGUANG ,  DE VIVO MICHAEL

IPC分类号： G01N33/53 ,  C07H21/04 ,  C07K14/00 ,  C07K14/705 ,  C12N5/00 ,  C12N5/02 ,  C12N5/06 ,  C12N5/08 ,  C12N5/10 ,  C12P21/02 ,  C12P21/06 ,  C12Q1/02 ,  G01N20060101 ,  G01N33/50 ,  G01N33/567 ,  G01N33/94

CPC分类号： C07K14/70571 ,  C12N2503/02 ,  C12N2510/00 ,  G01N33/5041 ,  G01N33/944

摘要： The present invention relates e.g., to QM-7 or QT-6 cells comprising a heterologous mutant nicotinic α7 acetylcholine receptor and/or a nucleic acid encoding it, or a fragment or variant thereof. In a preferred embodiment, the mutant nicotinic α7 acetylcholine receptor subunit has a mutation in the M2 domain. QM-7 and QT-6 cells of the invention are useful for, e.g., assays such as high throughput assays that measure the influx of cations, such as Ca++ ions, into a cell. Such assays can be used, e.g., to identify agents that modulate the expression and/or activity of a mutant cell-surface-expressed channel receptor (e.g., the nicotinic α7 receptor), and which thus modulate, e.g., among other functions, processes involved in the central nervous system, such as learning and memory.

公开(公告)号：EP1133571B1

公开(公告)日：2006-06-28

申请号：EP99963940.4

申请日：1999-11-22

申请人： Proteome Sciences, Inc.

发明人： CAMERON, Bruce, M., Sr. ,  ALLEN, Robert, C.

IPC分类号： C12Q1/46 ,  A61K38/46

CPC分类号： G01N33/523 ,  A61K38/465 ,  C12Q1/46 ,  C12Q2334/30 ,  C12Q2334/70 ,  C12Y301/01007 ,  G01N33/9406 ,  G01N33/944 ,  G01N2800/52 ,  Y10S435/975

摘要： The present invention provides novel methods and diagnostic kits for the objective measurement of the severity of pain or stress being experienced by a patient with a disorder, diagnosis and treatment for patients suffering from painful disorders, and monitoring the effectiveness of different pain-treatment protocols. Pain-measuring methods comprise collecting a sample from a patient and determining the presence of a pain-associated marker in the sample. Methods for alleviating pain comprise administrating a dose of a therapeutically effective amount of a composition to the patient wherein the dose is determined by the presence of a pain-associated marker in a biological sample obtained from the patient. Compositions for alleviating pain comprise substances that are pain-associated markers or agents that interfere with pain-associated markers, and block or modulate the progression of pain perceived by the patient.

摘要翻译： 本发明提供了用于客观测量患有疼痛障碍患者的病症，诊断和治疗的患者经历的疼痛或压力的严重程度以及监测不同疼痛治疗方案的有效性的新颖方法和诊断试剂盒。 疼痛测量方法包括从患者收集样品并确定样品中疼痛相关标志物的存在。 减轻疼痛的方法包括向患者施用治疗有效量的组合物的剂量，其中通过患者获得的生物样品中疼痛相关标志物的存在来确定该剂量。 用于缓解疼痛的组合物包括与疼痛相关的标记物或干扰疼痛相关标志物的试剂以及阻断或调节患者感觉到的疼痛进展的物质。

公开(公告)号：EP1613341A2

公开(公告)日：2006-01-11

申请号：EP04727963.3

申请日：2004-04-16

申请人： Université de Lausanne ,  UNIVERSITE DE GENEVE

发明人： CHIMIENTI, Fabrice, c/o Unite de dermatologie ,  HOGG, Ronald, c/o Dept. de Physiologie, CMU ,  HUBER, Marcel, c/o Unite de dermatologie ,  BERTRAND, Daniel, c/o Dept. de Physiologie, CMU ,  HOHL, D., c/o Unite de dermatologie, Hospices/CHUV

IPC分类号： A61K38/17 ,  A61K39/395 ,  G01N33/50 ,  A61P17/02 ,  A61P17/06 ,  A61P25/00

CPC分类号： G01N33/6896 ,  A61K38/177 ,  G01N33/6881 ,  G01N33/944 ,  G01N2333/4719 ,  G01N2500/00

摘要： Disclosed herein is the use of SLURP-1 for the treatment or prevention of neurological disorders,and for the treatment or prevention of skin pathologies.The invention further discloses the use of SLURP-1 for the modulation of acetylcholine receptor activity.Antibodies generated against SLURP-1 and related proteins are also disclosed.

公开(公告)号：EP1611128A2

公开(公告)日：2006-01-04

申请号：EP04720670.1

申请日：2004-03-15

申请人： Pharmacia & Upjohn Company LLC

发明人： ROGERS, Bruce Nelsen ,  PIOTROWSKI, David Walter ,  MARGOLIS, Brandon Jerome, Eli Lilly and Company ,  MYERS, Jason, Kenneth ,  GROPPI, Vincent Edward Jr. ,  RUDMANN, Daniel, Gregory

IPC分类号： C07D413/12 ,  C07D417/12 ,  A61K31/4439 ,  A61K31/433 ,  A61K31/427 ,  A61K31/422 ,  A61K31/42

CPC分类号： C07D417/12 ,  C07D413/12 ,  G01N33/6893 ,  G01N33/944 ,  Y02A50/58

摘要： The invention provides compounds of Formula I: wherein A, B, and X are described herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which alpha7 nAChR is known to be involved.